| 1 |
35037417 | PD-L1 and PD-L2 expression in pancreatic ductal adenocarcinoma and their correlation with immune infiltrates and DNA damage response molecules. | 2022 May |
1 |
| 2 |
35169863 | Differential expression of PD‑L1 and PD‑L2 is associated with the tumor microenvironment of TILs and M2 TAMs and tumor differentiation in non‑small cell lung cancer. | 2022 Apr |
2 |
| 3 |
35346570 | Evaluation of PD-L1 (E1L3N, 22C3) expression in venous tumor thrombus is superior to its assessment in renal tumor in predicting overall survival in renal cell carcinoma. | 2022 May |
2 |
| 4 |
35521773 | Expression and clinical significance of VISTA and PD-L1 in adrenocortical carcinoma. | 2022 May 27 |
2 |
| 5 |
35596539 | An integrated biomarker of PD-L1 expression and intraepithelial CD8+ T cell infiltration was associated with the prognosis of lung cancer patients after intracranial resection of brain metastases. | 2022 May 20 |
3 |
| 6 |
33071109 | PD-L1 expression in tumor-infiltrating lymphocytes (TILs) as an independent predictor of prognosis in patients with pN0 bladder cancer undergoing radical cystectomy. | 2021 Mar |
2 |
| 7 |
33196892 | Clinicopathological and molecular characteristics associated with PD-L1 expression in non-small cell lung cancer: a large-scale, multi-center, real-world study in China. | 2021 May |
2 |
| 8 |
33782193 | Validation of multiplex immunofluorescence and digital image analysis for programmed death-ligand 1 expression and immune cell assessment in non-small cell lung cancer: comparison with conventional immunohistochemistry. | 2021 Mar 29 |
1 |
| 9 |
33930847 | Tumor microenvironment disparity in multiple primary lung cancers: Impact of non-intrinsic factors, histological subtypes, and genetic aberrations. | 2021 Jul |
1 |
| 10 |
34136742 | Analytical Concordance of PD-L1 Assays Utilizing Antibodies From FDA-Approved Diagnostics in Advanced Cancers: A Systematic Literature Review. | 2021 Jun |
3 |
| 11 |
34217914 | Programmed cell death ligand-1 expression and survival in a cohort of patients with non-small cell lung cancer receiving first-line through third-line therapy in Denmark. | 2021 Aug |
1 |
| 12 |
34266881 | Multi-institutional TSA-amplified Multiplexed Immunofluorescence Reproducibility Evaluation (MITRE) Study. | 2021 Jul |
1 |
| 13 |
34272092 | PD-L1 expression in tumor cells is associated with a favorable prognosis in patients with high-risk endometrial cancer. | 2021 Sep |
4 |
| 14 |
34326649 | Expression of B7-H3 Correlates with PD-L1 and Poor Prognosis in Patients with Cervical Cancer. | 2021 |
1 |
| 15 |
34454491 | Lymphocyte activating gene 3 protein expression in nasopharyngeal carcinoma is correlated with programmed cell death-1 and programmed cell death ligand-1, tumor-infiltrating lymphocytes. | 2021 Aug 28 |
1 |
| 16 |
34559865 | Immunohistochemical comparison of three programmed death-ligand 1 (PD-L1) assays in triple-negative breast cancer. | 2021 |
1 |
| 17 |
34900743 | Prognostic Significance of PD-L1 Expression In Patients With Primary Oropharyngeal Squamous Cell Carcinoma: A Meta-Analysis. | 2021 |
1 |
| 18 |
30411509 | Association between PD-L1 expression and lymph node metastasis in cutaneous squamous cell carcinoma. | 2020 Apr |
2 |
| 19 |
31343994 | Foci of Programmed Cell Death-Ligand 1 (PD-L1)-positive Tumor Areas With Tumor-infiltrating Leukocytes (TILs) Evocative of a PD-1/PD-L1-related Adaptive Immune Resistance are Frequent in Merkel Cell Carcinoma. | 2020 Jan |
1 |
| 20 |
31872892 | Comparative analysis of programmed cell death ligand 1 assays in renal cell carcinoma. | 2020 Jul |
2 |
| 21 |
31897588 | Usefulness of [18F]fluorodeoxyglucose PET/CT for evaluating the PD-L1 status in nasopharyngeal carcinoma. | 2020 May |
3 |
| 22 |
31959546 | Comprehensive Assessment of Immuno-oncology Biomarkers in Adenocarcinoma, Urothelial Carcinoma, and Squamous-cell Carcinoma of the Bladder. | 2020 Apr |
1 |
| 23 |
32516834 | The tumor immune microenvironment and its implications for clinical outcome in patients with oropharyngeal squamous cell carcinoma. | 2020 Oct |
1 |
| 24 |
33380650 | Good prognostic factor in patients with nonmetastatic nasopharyngeal carcinoma: Programmed death ligand-1 expression in tumor cells. | 2020 Dec |
1 |
| 25 |
30253973 | Correlation of PD-L1 Expression with Tumor Mutation Burden and Gene Signatures for Prognosis in Early-Stage Squamous Cell Lung Carcinoma. | 2019 Jan |
1 |
| 26 |
30296523 | PD-L1 expression on tumor cells associated with favorable prognosis in surgically resected esophageal squamous cell carcinoma. | 2019 Feb |
2 |
| 27 |
31019901 | Increased Expression of Programmed Death-Ligand 1 in Infiltrating Immune Cells in Hepatocellular Carcinoma Tissues after Sorafenib Treatment. | 2019 Mar |
1 |
| 28 |
31129768 | PD-L1 is a double-edged sword in colorectal cancer: the prognostic value of PD-L1 depends on the cell type expressing PD-L1. | 2019 Jul |
3 |
| 29 |
31190987 | Clinicopathological and prognostic value of PD-L1 in urothelial carcinoma: a meta-analysis. | 2019 |
2 |
| 30 |
31260834 | A Minimum Of 100 Tumor Cells in a Single Biopsy Sample Is Required to Assess Programmed Cell Death Ligand 1 Expression in Predicting Patient Response to Nivolumab Treatment in Nonsquamous Non-Small Cell Lung Carcinoma. | 2019 Oct |
7 |
| 31 |
31359214 | Prognostic and clinicopathological value of PD-L1 expression in primary breast cancer: a meta-analysis. | 2019 Nov |
2 |
| 32 |
31366557 | Neoadjuvant Chemotherapy Increases PD-L1 Expression and CD8+ Tumor-infiltrating Lymphocytes in Esophageal Squamous Cell Carcinoma. | 2019 Aug |
1 |
| 33 |
31499335 | PD-L1 expression on tumor-infiltrating immune cells is highly associated with M2 TAM and aggressive malignant potential in patients with resected non-small cell lung cancer. | 2019 Oct |
7 |
| 34 |
28815764 | Aligning digital CD8+ scoring and targeted next-generation sequencing with programmed death ligand 1 expression: a pragmatic approach in early-stage squamous cell lung carcinoma. | 2018 Jan |
1 |
| 35 |
29378266 | Association of PD-L1 Expression with Tumor-Infiltrating Immune Cells and Mutation Burden in High-Grade Neuroendocrine Carcinoma of the Lung. | 2018 May |
1 |
| 36 |
29405663 | Cytologic-histologic correlation of programmed death-ligand 1 immunohistochemistry in lung carcinomas. | 2018 Apr |
1 |
| 37 |
29431467 | Correlation Between Programmed Death Receptor-1 Expression in Tumor-Infiltrating Lymphocytes and Programmed Death Ligand-1 Expression in Non-Small Cell Lung Carcinoma. | 2018 Nov |
3 |
| 38 |
29467945 | A comparative study of PD-L1 immunohistochemical assays with four reliable antibodies in thymic carcinoma. | 2018 Jan 23 |
3 |
| 39 |
29672367 | Characterization of PD-L1 and PD-1 Expression and CD8+ Tumor-infiltrating Lymphocyte in Epstein-Barr Virus-associated Nasopharyngeal Carcinoma. | 2018 Dec |
3 |
| 40 |
29673110 | Programmed death-ligand 1 expression in gastric cancer: correlation with mismatch repair deficiency and HER2-negative status. | 2018 Jun |
2 |
| 41 |
29707344 | Correlation and prognostic significance of PD-L1 and P53 expression in resected primary pulmonary lymphoepithelioma-like carcinoma. | 2018 Mar |
3 |
| 42 |
30077124 | The role of immune microenvironment in small-cell lung cancer: Distribution of PD-L1 expression and prognostic role of FOXP3-positive tumour infiltrating lymphocytes. | 2018 Sep |
2 |
| 43 |
30216999 | Chromogenic Multiplex Immunohistochemistry Reveals Modulation of the Immune Microenvironment Associated with Survival in Elderly Patients with Lung Adenocarcinoma. | 2018 Sep 13 |
1 |
| 44 |
30304846 | Low PD-L1 Expression Strongly Correlates with Local Recurrence in Epstein-Barr Virus-Positive Nasopharyngeal Carcinoma after Radiation-Based Therapy. | 2018 Oct 9 |
2 |
| 45 |
30449485 | Differences in PD-L1 expression on tumor and immune cells between lung metastases and corresponding primary tumors. | 2018 Dec |
3 |
| 46 |
27629881 | Clinicopathological features of programmed death ligand 1 expression with tumor-infiltrating lymphocyte, mismatch repair, and Epstein-Barr virus status in a large cohort of gastric cancer patients. | 2017 May |
1 |
| 47 |
28137741 | PD-L1 protein expression assessed by immunohistochemistry is neither prognostic nor predictive of benefit from adjuvant chemotherapy in resected non-small cell lung cancer. | 2017 Apr 1 |
1 |
| 48 |
28549836 | Heterogeneity of Tumor and Immune Cell PD-L1 Expression and Lymphocyte Counts in Surgical NSCLC Samples. | 2017 Nov |
2 |
| 49 |
28969052 | PD-1 and PD-L1 co-expression predicts favorable prognosis in gastric cancer. | 2017 Sep 8 |
2 |
| 50 |
28978000 | PD-L1 expression in bladder cancer and metastasis and its influence on oncologic outcome after cystectomy. | 2017 Sep 15 |
4 |